Intravitreal injection of anti vascular endothelial growth factor agent, Lucentis (ranibizumab), for the treatment of retinopathy of prematurity
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2017
Price : $35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- 03 Dec 2017 Planned End Date changed from 1 Jun 2019 to 30 Jun 2019.
- 03 Dec 2017 Status changed from not yet recruiting to discontinued.
- 10 Jul 2014 New trial record